AI Agents Find Drug Targets With Single-Cell Evidence Are 48% More Likely to Reach Market
james_y_zou · x · 2026-09-18
As part of the Virtual Biotech system published in Science, Stanford's James Zou group shows that multi-agent AI can integrate single-cell, cell-cell communication, spatial and clinical genomics data to generate disease-mechanism insights, flagging B7-H3 as a promising lung cancer target. By analyzing large-scale clinical trial data, the agents found that drug targets supported by single-cell evidence are 48% more likely to reach market, a signal that can help the industry prioritize targets.
More from AGI Musings
- wordgrammer: calling EA 'just utilitarianism' is like calling woke 'just Sartre' — wordgrammer · 2026-09-18
- Grade inflation kills college's talent-signaling role, economist warns — paulnovosad · 2026-09-18
- Everyone gets an A: professor points to grade inflation driving students to skip class for interviews — paulnovosad · 2026-09-18
- Sentdex: the 'only a few people can do AI safety work' claim is silly — the field is too homogeneous — Sentdex · 2026-09-18
- 'Wanting another 100 healthy years is controversial?' — the case for AI-driven longevity — VraserX · 2026-09-18
- Oxford AI ethicist Carissa Véliz on AI risks, chatbots, and democracy — CarissaVeliz · 2026-09-18